Create New Share
Please enter the email address below of the person you would like to share this article with.
An email will be sent to the recipient with a link to this chosen article.
A source for healthcare professionals to access the latest data and information on the diagnosis, treatment and management of patients with gut related disorders
Teruel C et al. World J Gastrointest Pharmacol Ther 2016;7:78–90.
Patients with inflammatory bowel disease (IBD) frequently experience symptoms similar to irritable bowel syndrome (IBS) whilst in remission. Although in remission, IBD patients with IBS have an impaired quality of life and are more likely to experience anxiety or depression than their asymptomatic counterparts. IBD-IBS is likely to be secondary to other factors, such as increased epithelial permeability, colonic dysmobility and intestinal hypersensitivity.
IBS-type symptoms have been reported in approximately 33% of IBD patients in remission. However, prevalence data is variable because of varying definitions of remission, and heterogeneous diagnostic and exclusion criteria. It is as yet unclear why some patients remain asymptomatic while others experience IBS-like symptoms of functional origin.
It is not easy to define remission in IBD as it encompasses a range of criteria including the absence of symptoms and identification of intestinal mucosal healing. Endoscopy is the most reliable test to determine the remission status of the patient, but it is invasive and uncomfortable.
Rome III criteria are typically used to diagnose functional symptoms of IBS in IBD patients in remission. IBS is characterised by abdominal pain or discomfort associated with changes in the frequency or consistency of bowel movements. There are no agreed definitions that can diagnose IBS-like symptoms in quiescent IBD.
Treatment strategies for IBD patients with IBS are not well defined, and patients are usually treated with IBS treatments, including dietary changes, antidepressants, antispasmodics and probiotics. A step-by-step approach to devising treatment strategies is required to resolve inflammation and to address the symptoms that impair the quality of life and psychological well-being of these patients.
Job number: JB57410GBs Date of Preparation: June 2019
You must be registered to GutNews.org
to view or download these files
Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohn’s disease
In patients with Crohn’s disease who had a prior surgical resection there was a modest correlation between the length of ileal resection and the severity of bile acid malabsorption (BAM), as defined by tauroselcholic (75selenium) acid (SeHCAT) retention values. Response to bile salt sequestrant therapy was not dependent on SeHCAT retention values.
Are you a healthcare professional?
This educational website is developed by GE Healthcare for educational purposes. The information contained within this website is intended for healthcare professionals. By entering this website you are confirming that you are a healthcare professional.
This link opens another website that is not under the review or control of GE Healthcare Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.